Between 2012-2014, Novartis sponsored the highest number of clinical trials in the UK compared to any other commercial sponsor.
Novartis has invested £5.7 million to help the Structural Genomics Consortium based at Oxford and Toronto Universities since 2007. This focuses on research into the 3D structures of proteins, chemical probes and biological assays relevant to drug discovery in chronic inflammatory diseases. Research is released into the public domain unrestricted and not patented, to speed up drug discovery.
Clinical trials are research studies intended to answer scientific questions and find better ways to treat or prevent diseases. All drugs enter the clinic via proof-of-concept trials, small-scale studies designed to get an early read on a drug’s safety and effectiveness, and to help find and advance the most promising drug candidates. Wherever possible, especially when molecular pathways are shared, several diseases are explored in parallel. If the proof-of-concept study is successful, a medicine typically moves into full clinical development.
The development process varies by division because of the different types of products involved.
Participating in a Novartis clinical trial
Clinical studies are conducted to determine whether a new treatment has an acceptable safety and efficacy profile. Such studies are possible because volunteers (healthy volunteers and patients) agree to participate and try new medicines.
Novartis makes a conscientious effort to ensure that patients and healthcare professionals are informed about ongoing clinical trials by making trial information publicly available. Novartis is currently conducting clinical trials worldwide in a number of diseases. More information about ongoing Novartis sponsored clinical trials in the UK and worldwide can be found at:
Providing information on clinical trials and their results serves everyone, including study participants, patients and healthcare providers. For more than 15 years, Novartis has supported data transparency and was on of the first to publish trial results of innovative medicines within one year of study completion, regardless of outcome.
We recognise the importance of informing the public about the results of our interventional clinical trials for innovative compounds, regardless of the outcome. We make the results of our clinical trials publicly available through peer-reviewed publications and posting of results on the Novartis clinical trial results database and other online public databases.